Working at the intersection of innovation, technology and product development, I manage the external innovation portfolio for antibody discovery and protein engineering in R&D. This includes identifying novel technologies for our core therapeutic areas, as well as emerging platforms like cell therapy, peptide delivery, oral biologics and adeno associated virus (AAV), and building next generation antibody conjugate technologies for tissue targeting and to prevent off target toxicity.
My role sees me liaise closely with our therapeutic area heads and business development colleagues to lead and execute the evaluation of novel technologies through data-driven feasibility studies. I also design and run open innovation challenges and scientific advisory boards to ensure we address internal gaps and identify the most exciting technologies and collaborators.
With over 20 years of experience in pharma/biotech, I started my career as a research scientist in academia after gaining my PhD from Purdue University in Chemistry and Materials Science & Engineering.
Over my career, I have led teams to secure a number of novel drug delivery approvals such as an injectable biologic drug-device combination product, an active transdermal patch and a dry powder inhalation device. I also have more than 25 peer reviewed publications and 2 book chapters, as well as several granted patents.

What excites me about my role is the ability to work across our core therapeutic areas and identify disruptive technologies with the aim of creating life changing medicines for patients. Developing novel product concepts and treatment possibilities with internal scientists and external collaborators through joint development brings the best of both worlds and makes my work very engaging and intellectually rewarding.

金沙登录平台入口
金沙登录平台入口
2017: Global excellence award for the best patent 金沙登录平台入口

金沙登录平台入口
金沙登录平台入口
2013: Exceptional Team Performance award金沙登录平台入口

CURRENT ROLE
金沙登录网址
2017-19
金沙登录网址
2019
金沙登录网址
2014-2017
金沙登录网址
金沙登录网址
Nanotherapeutics in oral and parenteral drug delivery: Key learnings and future outlooks as we think small.金沙登录平台入口
Tyagi P, Subramony JA. J Controlled Release, 2018. 272; 159–168.
Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer.金沙登录平台入口
Chen F, et al. Nature Comms 2018. 9:4141
Oral peptide delivery: Translational challenges due to physiological effects.金沙登录平台入口
Tyagi P, Pechenov S, Subramony JA. J Controlled Release. 2018. 287; 167–176
Improving Drug-Like Properties of Insulin and GLP-1 via Molecule Design and Formulation and Improving Diabetes Management with Device & Drug Delivery.金沙登录平台入口
Pechenov S, Bhattacharjee H, Yin D, Mittal S, Subramony JA. Adv Drug Deliv Rev. 2017.
Engineered in-situ depot-forming hydrogels for intratumoral drug delivery.金沙登录平台入口
Fakhari A, Subramony JA. J Controlled Release 2015. 220; 465–475
Understanding Subcutaneous Tissue Pressure for Engineering Injection Devices for Large Volume Protein Delivery.金沙登录平台入口
Doughty DV, Clawson CZ, Lambert W, Subramony JA. J Pharm Sci. 2016 105(7):2105-13